Novo Nordisk Gets Close to Launching the First Oral GLP-1 Drug for Diabetes
Novo Nordisk has positive Phase III trial results for its oral version of semaglutide, a…
Novo Nordisk has positive Phase III trial results for its oral version of semaglutide, a…
Numab and Intarcia have a first candidate to combine a tri-specific antibody fragment with a…
Intarcia will develop a drug delivery device for HIV prevention that can significantly reduce dosing…
Given the rates of diabetes reaching 'epidemic proportions', we figured it was time to have…
Numab and Intarcia have achieved key milestones in the development of therapeutic antibody fragments. This…
Treatment of diabetes hasn't changed so much since the development of first human insulin by…
Immuno-oncology is a Biotech field that is more than just hype - it could solve…
The French company Servier wants to invest one billion euros by a partnering with the…